Medicines with dominant position in the Russian market

| By | FAS Russia
0
2254

The Russian Federal Antimonopoly Service (FAS) named 16 medicinal products holding more than 50% of their commercial markets. This information is based on the analysis of competition in the commercial market of several drugs published on the official web portal of FAS.

Medicines with dominant position

INN/Manufacturer Geographic Boundaries of Commercial Market Market Share Time Interval of Commercial Market Study (year)
Alendronic acid+Colecalciferol /MSD Russian Federation More than 50% 2015
Alpha-1-proteinase inhibitor (human) / Kamada Russian Federation More than 50% 2015
Anti-Inhibitor Coagulant Complex / Baxter AG Russian Federation More than 50% 2015
Antithrombin III / Baxter AG Russian Federation More than 50% 2015
Bosentan /Actelion Pharmaceuticals Russian Federation More than 50% 2016
Drospirenone+Estradiol / Bayer Russian Federation More than 50% 2016
Caspofungin / MSD Russian Federation More than 50% 2015
Lapatinib / Novartis Russian Federation More than 50% Oct 2015 – Dec 2016
Sodium fumarate / JSC Firma Medpolymer Russian Federation More than 50% 2015
Nitrofural / LLC Anzhero-Sudzhensky Chemical and Pharmaceutical Plant Russian Federation More than 50% 2015
Protein C human / Baxter AG Russian Federation More than 50% 2015
Coagulation Factors II, VII, IX, X in combination (Prothrombin Complex) / Baxter AG Russian Federation More than 50% 2015
Humalog / Eli Lilly Russian Federation More than 50% 2015
Humalog Mix / Eli Lilly Russian Federation More than 50% 2015
Eptacog alfa / CJSC Generium Russian Federation More than 50% 2015
Eculizumab / PJSC Pharmimex Russian Federation More than 50% 2015